DOCSLIB.ORG

Physostigmine As an Antidote

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Physostigmine As an Antidote Peer Reviewed Title: Physostigmine as an Antidote Journal Issue: Western Journal of Emergency Medicine, 2(4) Author: Stilson, Matthew, University of California, Irvine Medical School Kelly, Kevin MD, University of California, Irvine Medical Center Suchard, Jeffrey MD, University of California, Irvine Medical Center Publication Date: 2001 Publication Info: Western Journal of Emergency Medicine, Department of Emergency Medicine (UCI), UC Irvine Permalink: http://escholarship.org/uc/item/3c0240c3 Keywords: Physostigmine License Statement: This is an Open Access article distributed under the terms of the Creative Commons Non- Commercial Attribution License, which permits its use in any digital medium, provided the original work is properly cited and not altered. For details, please refer to http://creativecommons.org/ licenses/by-nc/3.0/. Authors grant Western Journal of Emergency Medicine as well as the National Library of Medicine a nonexclusive license to publish the manuscript. Western Journal of Emergency Medicine is produced by the eScholarship Repository and bepress. eScholarship provides open access, scholarly publishing services to the University of California and delivers a dynamic research platform to scholars worldwide. The California Journal of Emergency Medicine II:4, October 2001 page 47 Toxicology Review uncharged. lipophilic, and easily crosses the blood-brain barrier.- This Physostigmine as an Antidote action allows physostigmine to reverse toxic CNS effects, whereas other carba~natedmgs that are charged quaternary a~nines(such as neostigmine and pyridostigmine) will only reverse peripheral signs Matthew Stilson and symptoms. Physostigmine's ability to reverse central effects led University of California; Irvine Medical School, Irvine, CA to its trade name of AntiliriurnB, since it can reverse the delirium Kevin Kelly. MD associated with anticholinergic toxicity. Jeffrey Suchard, MD University of California, Irvine Medical Center, Orange, CA Indications: Physostigmine treatment may be indicated for patients with moderate to severe anticholinergic poisoning with evidence of both Introduction: peripheral and central toxicity.Vhysostigmine is not generally con- Rapid treatment of patients with anticholinergic toxicity sidered a first-line agent, and should probably be reserved for paticnrs in the Ernergcncy Department (ED) has remained problematic for with potentially life-threatening complications of anticholinergic tox- many years. These patients are often agitated. uncooperative, and icity that are unresponsive to standard treatment regimens. Such unable to provide a clear history. Physostigmine is a specific anti- complications include severe agitation, seinires. persistent hyperten- dote for anticholinergic toxicity. yet its popularity has waned due to sion, and heinodyna~niccompromise secondary to tachycardia (i.e. controversy surrounding its potential central nervo~issystem and unstable narrow complex dysl-rhythmias). cardiac toxicities. In this brief review, we discuss physostigmine's In addition to a therapeutic role in clear-cut cases of anticho- history, method of action. indications, contraindications, dosing, linergic poisoning, physostigmine also has a potential diagnostic role. and its use in the ED. In patients with altered levels of consciousness, who bv relevant his- tory and examination may be suffe~ingfrom anticholinergic poisoning, Background: a test dose of physostigmine may help to confinn the diagnosis. If the Physostigmine is a naturally-occurring compound first patient's mental status significantly improves, more invasive and time- isolated from the extract of the West African Calabar bean (PIzysos- consuming diagnostic tests. such as lumbar puncture and cranial com- tipnza verzoszcn~)in 1864. In the same year, a crude Calabar bean puted tornogaphy, may be avoided;'.' this is particularly true if thc extract was first used as an antidote for anticholinergic toxicity among paticnt is then able to identify the substance ingested. One caution three prisoners ingesting belladonna.' Sincc that time. physostig- must bc noted: physostigrnine is an "analeptic" agent and may cause mine has been used to trcat glaucoma, post-operative ileus. and non-specific arousal whcn used in the presence of many drugs causing atropine-induced coma.' Physostigminc's popularity as an antidote depressed mental status. Therefore, minor improvelnents in a patient's grew in the late 1960s and 1970s. particularly for the treatment of level of consciousness do not prove that they wcre poisoned with an altered mental status associated with tricyclic antidepressant poi- anticholinergic agent. soning." A 1980 report of asystole complicating physostigmine use in two patients with serious tricyclic antidepressant poisoning4 Dosing and Precautions: heralded a retreat fi-om indiscriminate use of the antidote. More The initial dose of physostigmine is 1-2 mg in adults and recently. opinion has shifted again towards favoring the cautious use 0.02 mglkg in children administered slowly IV over at least 5 minutes. of physostiglnine as an antidote in selected cases of anticholinergic Many physicians are even Inore cautious, and utilize 0.5 mg aliquots. toxicity.' titrated slowly to desired effect. Rapid administration is associated with induction of seizures.' Bccause of its short half-life and rapid Clinical Pharmacology: elimination, the clinical effects of physostigmine are short in duration. Acetylcholine is a neurotransmitter that acts at muscar- Repeat dosing every 20-60 minutes may be needed to correct the inic and nicotinic receptors of the cholinergic nervous system. Un- recul-rence of life-threatening conditions initially treated with the first der notmal conditions, the action of acetylcholine is quickly tcrmi- dose."' Continuous physostigmine infiisions have been reported but nated by the enzyme acetylcholinesterase (Ach) found in the syn- are not rccommended. Although effective in reversing anticholinergic aptic cleft. Drugs and other compounds that are typically classified toxicity, treatment with physostignlinc can lead to adverse side-ef- as "anticholinergic" are actually antimuscarinic, since they block the fects and complications. Excessive doses of physostigmine may in- effect of acetylcholine at rnuscarinic receptors within the central duce cholinergic toxicity. Prior to administering physostigmine, rcac- nervous system, in peripheral ganglia, and on effector organs of the tion to potential complications should be anticipated. Urinary outlet autonomic nervous system. namely the exocrine glands (bronchial, obstl-~lctioncan be prevented by the placement of a Foley catheter and sweat. lacrimal); and cardiac and smooth muscles. Such anticholin- bedside s~lctionshould be immediately available if needed to clear crgic agents include many antihistamines, antiparkinsonian dnlgs, excess salivation, bronchial secretions. or emesis. The patient should antipsychotics, antispasmodics. tricyclic antidepressants, belladonna also be placed on continuous electrocardiographic and pulse oximetry alkaloids and co~npoundsfound in several other poisonous plants monitoring. Close physician supervision during and immediately fol- and fi~ngi.~ lowing physostigrnine administration is desirable. Atropine should Physostigmine is a carbamate that reversibly inhibits ace- also be rapidly available to counteract excessive cholinergic tone, and tylcholinesterase. Physostiglnine acts as a competitive substrate is administered IV at a dose equal to half the initial dose of physostig- for Ach, allowing acetylcholine to accumulate in the synaptic clefts mine if such complications occi~r.~Serious but relatively infrequent and overcome the blockade of muscarinic receptors by the anticho- linergic agents. Because physostigmine is a tertiary amine. it is complications, such as seizures, symptonlatic bradycardia, and bron- The California Journal of Emergency Medicine II:4, October 2001 page 48 chospasm, hake been assoc~atedw~th physostlgnnne treatment ' ' firm the diagnosis and obviate the need for additional invasive or expcnsive testing. Further review and prospective analysis concern- Contraindications: ing its use in the setting of TCA overdose or QRS interval prolonga- The contraindications to physostigrninc use form one of tion is needed to provide clear-cut contraindications. When used with the most controversial issues regal-ding the dn~g.Several conditions proper precautions. however, physostig~ninecan be a valuable tool in listed as contraindications are predictable, as enhancing cholinergic the ED armamentarium. tone may exacerbate them, including asthma. chronic obstnlctive pulmonary disease. atherosclerotic heart disease. bradycardia, pe- References: ripheral vascular disease, genitourinary and gastrointestinal obstruc- tion,'.~~~Many sources list tricyclic antidepressant (TCA) over- Aquilonius SM, Hedstrand U. The Use of Physostig~nineas an dose and prolongation of the QRS complex on the ECG 2 0.10 scc Antidote in Tricyclic Anti-depressant Intoxication. Acrn Arznest as absolute contraindications to physostigmine." Use in these Scarld 1978;22:40-5. circumstances has been associated with severe bradyarrhythrnias Walker WE, Levy RC, Hanenson IB. Physostigmine - Its Use and asystole.' and Abuse. JACEP 1976;5:436-9. The contraindication against physostigmine use in TCA Burks JS, Walker JE, Rumack BH, Ott JE. Tricyclic Antidepres- overdose patients has reached the status of treatment dogma de- sant Poisoning: Reversal of Coma, Choreoathetosis,
Load more

Recommended publications
  • Mapping the Dissociated Body
    Lesley University DigitalCommons@Lesley Graduate School of Arts and Social Sciences Expressive Therapies Capstone Theses (GSASS) Spring 5-16-2020 Mapping the Dissociated Body Elizabeth Hough [email protected] Follow this and additional works at: https://digitalcommons.lesley.edu/expressive_theses Part of the Social and Behavioral Sciences Commons Recommended Citation Hough, Elizabeth, "Mapping the Dissociated Body" (2020). Expressive Therapies Capstone Theses. 239. https://digitalcommons.lesley.edu/expressive_theses/239 This Thesis is brought to you for free and open access by the Graduate School of Arts and Social Sciences (GSASS) at DigitalCommons@Lesley. It has been accepted for inclusion in Expressive Therapies Capstone Theses by an authorized administrator of DigitalCommons@Lesley. For more information, please contact [email protected], [email protected]. Running Head: MAPPING THE DISSOCIATED BODY 1 Mapping the Dissociated Body Elizabeth Hough Lesley University Running Head: MAPPING THE DISSOCIATED BODY 2 Abstract This capstone thesis explored the use of body mapping and body scans as a tool for assessing and tracking somatic dissociation and embodiment. The researcher utilized a client- centered approach and mindfulness-based interventions and theory to ground the work with the clients. While there were a variety of questionnaire-based tools for assessing dissociation with clients, many of them were lacking in the somatic component of dissociation. The available assessments were also exclusively self-reported and written or verbal, which had the potential to result in biased reporting. Clients may have also struggled to identify their level of somatic dissociation due to an inherent disconnection or dismissal of their somatic experience. This research described two case studies in which body scans and body mapping were utilized as a method to assess and track the client’s level of body dissociation and embodiment.
    [Show full text]
  • Modifications on the Basic Skeletons of Vinblastine and Vincristine
    Molecules 2012, 17, 5893-5914; doi:10.3390/molecules17055893 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Modifications on the Basic Skeletons of Vinblastine and Vincristine Péter Keglevich, László Hazai, György Kalaus and Csaba Szántay * Department of Organic Chemistry and Technology, University of Technology and Economics, H-1111 Budapest, Szt. Gellért tér 4, Hungary * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel: +36-1-463-1195; Fax: +36-1-463-3297. Received: 30 March 2012; in revised form: 9 May 2012 / Accepted: 10 May 2012 / Published: 18 May 2012 Abstract: The synthetic investigation of biologically active natural compounds serves two main purposes: (i) the total synthesis of alkaloids and their analogues; (ii) modification of the structures for producing more selective, more effective, or less toxic derivatives. In the chemistry of dimeric Vinca alkaloids enormous efforts have been directed towards synthesizing new derivatives of the antitumor agents vinblastine and vincristine so as to obtain novel compounds with improved therapeutic properties. Keywords: antitumor therapy; vinblastine; vincristine; derivatives 1. Introduction Vinblastine (1) and vincristine (2) are dimeric alkaloids (Figure 1) isolated from the Madagaskar periwinkle plant (Catharantus roseus), exhibit significant cytotoxic activity and are used in the antitumor therapy as antineoplastic agents. In the course of cell proliferation they act as inhibitors during the metaphase of the cell cycle and by binding to the microtubules inhibit the development of the mitotic spindle. In tumor cells these agents inhibit the DNA repair and the RNA synthesis mechanisms, blocking the DNA-dependent RNA polymerase. Molecules 2012, 17 5894 Figure 1.
    [Show full text]
  • Carbamate Pesticides Aldicarb Aldicarb Sulfoxide Aldicarb Sulfone
    Connecticut General Statutes Sec 19a-29a requires the Commissioner of Public Health to annually publish a list setting forth all analytes and matrices for which certification for testing is required. Connecticut ELCP Drinking Water Analytes Revised 05/31/2018 Microbiology Total Coliforms Fecal Coliforms/ E. Coli Carbamate Pesticides Legionella Aldicarb Cryptosporidium Aldicarb Sulfoxide Giardia Aldicarb Sulfone Carbaryl Physicals Carbofuran Turbidity 3-Hydroxycarbofuran pH Methomyl Conductivity Oxamyl (Vydate) Minerals Chlorinated Herbicides Alkalinity, as CaCO3 2,4-D Bromide Dalapon Chloride Dicamba Chlorine, free residual Dinoseb Chlorine, total residual Endothall Fluoride Picloram Hardness, Calcium as Pentachlorophenol CaCO3 Hardness, Total as CaCO3 Silica Chlorinated Pesticides/PCB's Sulfate Aldrin Chlordane (Technical) Nutrients Dieldrin Endrin Ammonia Heptachlor Nitrate Heptachlor Epoxide Nitrite Lindane (gamma-BHC) o-Phosphate Metolachlor Total Phosphorus Methoxychlor PCB's (individual aroclors) Note 1 PCB's (as decachlorobiphenyl) Note 1 Demands Toxaphene TOC Nitrogen-Phosphorus Compounds Alachlor Metals Atrazine Aluminum Butachlor Antimony Diquat Arsenic Glyphosate Barium Metribuzin Beryllium Paraquat Boron Propachlor Cadmium Simazine Calcium Chromium Copper SVOC's Iron Benzo(a)pyrene Lead bis-(2-ethylhexyl)phthalate Magnesium bis-(ethylhexyl)adipate Manganese Hexachlorobenzene Mercury Hexachlorocyclopentadiene Molybdenum Nickel Potassium Miscellaneous Organics Selenium Dibromochloropropane (DBCP) Silver Ethylene Dibromide (EDB)
    [Show full text]
  • Pyridostigmine in the Treatment of Postural
    Pyridostigmine in the Treatment of Postural Orthostatic Tachycardia: A Single-Center Experience KHALIL KANJWAL, M.D.,* BEVERLY KARABIN, PH.D.,* MUJEEB SHEIKH, M.D.,* LAWRENCE ELMER, M.D., PH.D.,† YOUSUF KANJWAL, M.D.,* BILAL SAEED, M.D.,* and BLAIR P. GRUBB, M.D.* From the *Electrophysiology Section, Division of Cardiology, Department of Medicine, The University of Toledo, Toledo, Ohio; and †Department of Neurology, The University of Toledo College of Medicine, Health Science Campus, Toledo, Ohio Background: The long-term efficacy of pyridostigmine, a reversible acetyl cholinesterase inhibitor, in the treatment of postural orthostatic tachycardia syndrome (POTS) patients remains unclear. We report our retrospective, single-center, long-term experience regarding the efficacy and adverse effect profile of pyridostigmine in the treatment of POTS patients. Methods: This retrospective study included an extensive review of electronic charts and data collection in regards to patient demographics, orthostatic parameters, side-effect profile, subjective response to therapy, as well as laboratory studies recorded at each follow-up visit to our institution’s Syncope and Autonomic Disorders Center. The response to pyridostigmine therapy was considered successful if patient had both symptom relief in addition to an objective response in orthostatic hemodynamic parameters (heart rate [HR] and blood pressure). Three hundred patients with POTS were screened for evaluation in this study. Of these 300, 203 patients with POTS who received pyridostigmine therapy were reviewed. Of these 203 patients, 168 were able to tolerate the medication after careful dose titration. The mean follow- up duration in this group of patients was 12 ± 3 (9–15) months. Pyridostigmine improved symptoms of orthostatic intolerance in 88 of 203 (43%) of total patients or 88 of 172 (51%) who were able to tolerate the drug.
    [Show full text]
  • WO 2018/005077 Al O O© O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/005077 Al 04 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61K 31/78 (2006.01) C08J 7/04 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. C08G 59/77 (2006.01) (84) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of regional protection available): ARIPO (BW, GH, PCT/US20 17/037 176 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (22) International Filing Date: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 13 June 2017 (13.06.2017) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (25) Filing Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (26) Publication Language: English KM, ML, MR, NE, SN, TD, TG). (30) Priority Data: 62/356,918 30 June 2016 (30.06.2016) US Published: — with international search report (Art. 21(3)) (71) Applicant: ELEMENTIS SPECIALTIES, INC. [US/US]; 469 Old Trenton Road, East Windsor, NJ 085 12 (US). (72) Inventors: IJDO, Wouter; 1224 Bridle Estates Dri ve, Yardley, PA 19067 (US). CHEN, Yanhui; 4 Hal- stead Place, Princeton, NJ 08540 (US).
    [Show full text]
  • Corticosterone and Pyridostigmine/DEET Exposure
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Neurotoxicology Manuscript Author . Author Manuscript Author manuscript; available in PMC 2019 May 24. Published in final edited form as: Neurotoxicology. 2019 January ; 70: 26–32. doi:10.1016/j.neuro.2018.10.006. Corticosterone and pyridostigmine/DEET exposure attenuate peripheral cytokine expression: Supporting a dominant role for neuroinflammation in a mouse model of Gulf War Illness Lindsay T. Michalovicza, Alicia R. Lockera, Kimberly A. Kellya, Julie V. Millera, Zachary Barnesb,c, Mary Ann Fletcherb,c, Diane B. Millera, Nancy G. Klimasb,c, Mariana Morrisb, Stephen M. Lasleyd, and James P. O’Callaghana,* aHealth Effects Laboratory Division, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, Morgantown, WV, USA bInstitute for Neuro-Immune Medicine, Nova Southeastern University, Ft. Lauderdale, FL, USA cMiami Veterans Affairs Medical Center, Miami, FL, USA dDepartment of Cancer Biology & Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, IL, USA Abstract Gulf War Illness (GWI) is a chronic multi-symptom disorder experienced by as many as a third of the veterans of the 1991 Gulf War; the constellation of “sickness behavior” symptoms observed in ill veterans is suggestive of a neuroimmune involvement. Various chemical exposures and conditions in theater have been implicated in the etiology of the illness. Previously, we found that GW-related organophosphates (OPs), such as the sarin surrogate, DFP, and chlorpyrifos, cause neuroinflammation. The combination of these exposures with exogenous corticosterone (CORT), mimicking high physiological stress, exacerbates the observed neuroinflammation. The potential relationship between the effects of OPs and CORT on the brain versus inflammation in the periphery has not been explored.
    [Show full text]
  • XELJANZ (Tofacitinib)
    HIGHLIGHTS OF PRESCRIBING INFORMATION Psoriatic Arthritis (in combination with nonbiologic DMARDs) These highlights do not include all the information needed to use XELJANZ 5 mg twice daily or XELJANZ XR 11 mg once daily. (2.2) XELJANZ/XELJANZ XR safely and effectively. See full prescribing Recommended dosage in patients with moderate and severe renal information for XELJANZ. impairment or moderate hepatic impairment is XELJANZ 5 mg once daily. (2, 8.7, 8.8) ® XELJANZ (tofacitinib) tablets, for oral use Ulcerative Colitis ® XELJANZ XR (tofacitinib) extended-release tablets, for oral use XELJANZ 10 mg twice daily for at least 8 weeks; then 5 or 10 mg Initial U.S. Approval: 2012 twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to WARNING: SERIOUS INFECTIONS AND MALIGNANCY maintain response. (2.3) See full prescribing information for complete boxed warning. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment: half the total daily dosage Serious infections leading to hospitalization or death, including recommended for patients with normal renal and hepatic function. (2, 8.7, tuberculosis and bacterial, invasive fungal, viral, and other 8.8) opportunistic infections, have occurred in patients receiving Dosage Adjustment XELJANZ. (5.1) See the full prescribing information for dosage adjustments by indication If a serious infection develops, interrupt XELJANZ/XELJANZ XR for patients receiving CYP2C19 and/or CYP3A4 inhibitors; in patients until the infection is controlled. (5.1) with moderate or severe renal impairment or moderate hepatic Prior to starting XELJANZ/XELJANZ XR, perform a test for latent impairment; and patients with lymphopenia, neutropenia, or anemia.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Mechanism of Central Hypopnoea Induced by Organic Phosphorus
    www.nature.com/scientificreports OPEN Mechanism of central hypopnoea induced by organic phosphorus poisoning Kazuhito Nomura*, Eichi Narimatsu, Hiroyuki Inoue, Ryoko Kyan, Keigo Sawamoto, Shuji Uemura, Ryuichiro Kakizaki & Keisuke Harada Whether central apnoea or hypopnoea can be induced by organophosphorus poisoning remains unknown to date. By using the acute brainstem slice method and multi-electrode array system, we established a paraoxon (a typical acetylcholinesterase inhibitor) poisoning model to investigate the time-dependent changes in respiratory burst amplitudes of the pre-Bötzinger complex (respiratory rhythm generator). We then determined whether pralidoxime or atropine, which are antidotes of paraoxon, could counteract the efects of paraoxon. Herein, we showed that paraoxon signifcantly decreased the respiratory burst amplitude of the pre-Bötzinger complex (p < 0.05). Moreover, pralidoxime and atropine could suppress the decrease in amplitude by paraoxon (p < 0.05). Paraoxon directly impaired the pre-Bötzinger complex, and the fndings implied that this impairment caused central apnoea or hypopnoea. Pralidoxime and atropine could therapeutically attenuate the impairment. This study is the frst to prove the usefulness of the multi-electrode array method for electrophysiological and toxicological studies in the mammalian brainstem. Te pre-Bötzinger complex (preBötC) in the ventrolateral lower brainstem is essential for the formation of the unconscious breathing rhythm in mammals1,2. Tis is because the cyclic burst excitation generated from preBötC synchronizes with the respiratory rhythm through phrenic nerve fring and the diaphragmatic contractions, and destruction of preBötC causes the disappearance of the rhythm. Periodic respiratory burst excitation has also been confrmed from an island specimen derived by isolating preBötC in an island shape to block input from other neurons2.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis
    Florida International University FIU Digital Commons HWCOM Faculty Publications Herbert Wertheim College of Medicine 10-23-2019 Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis SP Singh Hitendra S. Chand S. Banerjee H. Agarwal V. Raizada See next page for additional authors Follow this and additional works at: https://digitalcommons.fiu.edu/com_facpub Part of the Medicine and Health Sciences Commons This work is brought to you for free and open access by the Herbert Wertheim College of Medicine at FIU Digital Commons. It has been accepted for inclusion in HWCOM Faculty Publications by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. Authors SP Singh, Hitendra S. Chand, S. Banerjee, H. Agarwal, V. Raizada, S. Roy, and M. Sopori Digestive Diseases and Sciences (2020) 65:141–149 https://doi.org/10.1007/s10620-019-05838-6 ORIGINAL ARTICLE Acetylcholinesterase Inhibitor Pyridostigmine Bromide Attenuates Gut Pathology and Bacterial Dysbiosis in a Murine Model of Ulcerative Colitis Shashi P. Singh1 · Hitendra S. Chand2 · Santanu Banerjee3 · Hemant Agarwal4 · Veena Raizada4 · Sabita Roy3 · Mohan Sopori1 Received: 30 March 2019 / Accepted: 10 September 2019 / Published online: 23 October 2019 © The Author(s) 2019 Abstract Background Ulcerative colitis (UC) is a Th2 infammatory bowel disease characterized by increased IL-5 and IL-13 expres- sion, eosinophilic/neutrophilic infltration, decreased mucus production, impaired epithelial barrier, and bacterial dysbiosis of the colon. Acetylcholine and nicotine stimulate mucus production and suppress Th2 infammation through nicotinic receptors in lungs but UC is rarely observed in smokers and the mechanism of the protection is unclear.
    [Show full text]
  • Examining the Therapist's Internal Experience When a Patient Dissociates in Session
    University of Pennsylvania ScholarlyCommons Doctorate in Social Work (DSW) Dissertations School of Social Policy and Practice Spring 5-13-2013 Do You Know What I Know? Examining the Therapist's Internal Experience when a Patient Dissociates in Session Jacqueline R. Strait University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations_sp2 Part of the Psychology Commons, and the Social Work Commons Recommended Citation Strait, Jacqueline R., "Do You Know What I Know? Examining the Therapist's Internal Experience when a Patient Dissociates in Session" (2013). Doctorate in Social Work (DSW) Dissertations. 36. https://repository.upenn.edu/edissertations_sp2/36 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations_sp2/36 For more information, please contact [email protected]. Do You Know What I Know? Examining the Therapist's Internal Experience when a Patient Dissociates in Session Abstract There is rich theoretical literature that cites the importance of the therapist’s use of self as a way of knowing, especially in cases where a patient has been severely traumatized in early life. There is limited empirical research that explores the in-session experience of therapists working with traumatized patients in order to support these claims. This study employed a qualitative design to explore a therapist’s internal experience when a patient dissociates in session. The aim of this study was to further develop the theoretical construct of dissociative attunement to explain the way that therapist and patient engage in a nonverbal process of synchronicity that has the potential to communicate dissociated images, affect or somatosensory experiences by way of the therapist’s internal experience.
    [Show full text]